The latest data in our current survey highlights geographical differences in the comorbidities experienced by people with diabetes along with satisfaction with their glucose control.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.